StemCell Therapy

Unity Biotechnology Inc (UBX) is around the bottom of the Biotechnology industry according to InvestorsObserver. UBX received an overall rating of 35, which means that it scores higher than 35 percent of all stocks. Unity Biotechnology Inc also achieved a score of 23 in the Biotechnology industry, putting it above 23 percent of Biotechnology stocks. Biotechnology is ranked 27 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 35 means the stock is more attractive than 35 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Unity Biotechnology Inc (UBX) stock is trading at $3.95 as of 1:21 PM on Monday, Oct 12, a rise of $0.17, or 4.6% from the previous closing price of $3.78. The stock has traded between $3.81 and $4.15 so far today. Volume today is 893,480 compared to average volume of 976,910.

Click Here to get the full Stock Score Report on Unity Biotechnology Inc (UBX) Stock.

Read more:
Does Unity Biotechnology Inc (UBX) Have What it Takes to be in Your Portfolio? - InvestorsObserver

This entry was posted on October 13, 2020 at 2:59 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |